US 12,402,610 B2
Methods and compositions for modulating innate lymphoid cell pathogenic effectors
Aviv Regev, Cambridge, MA (US); Piotr Bielecki, New Haven, CT (US); Richard Flavell, New Haven, CT (US); Monika Kowalczyk, Cambridge, MA (US); Samantha Riesenfeld, Cambridge, MA (US); Jan-Christian Huetter, Cambridge, MA (US); and Elena Torlai Triglia, Cambridge, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); and Yale University, New Haven, CT (US)
Filed by The Broad Institute, Inc., Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); and Yale University, New Haven, CT (US)
Filed on Nov. 12, 2019, as Appl. No. 16/681,050.
Claims priority of provisional application 62/758,117, filed on Nov. 9, 2018.
Prior Publication US 2020/0146269 A1, May 14, 2020
Int. Cl. A61K 38/22 (2006.01); A01K 67/0278 (2024.01); A61K 38/20 (2006.01); A61K 40/10 (2025.01); A61K 40/22 (2025.01); A61K 40/41 (2025.01); C12N 15/10 (2006.01); C12N 15/113 (2010.01); C12Q 1/6881 (2018.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); A61K 48/00 (2006.01); C12N 5/078 (2010.01); C12N 9/22 (2006.01); C12N 15/115 (2010.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01)
CPC A01K 67/0278 (2013.01) [A61K 38/20 (2013.01); A61K 40/10 (2025.01); A61K 40/22 (2025.01); A61K 40/416 (2025.01); C12N 15/102 (2013.01); C12N 15/113 (2013.01); C12Q 1/6881 (2013.01); G01N 33/5047 (2013.01); G01N 33/56972 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0325 (2013.01); A01K 2267/0368 (2013.01); A01K 2267/0387 (2013.01); A61K 48/00 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C12N 5/0634 (2013.01); C12N 9/22 (2013.01); C12N 15/115 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12Q 2600/158 (2013.01)] 29 Claims
 
1. A method of treating skin inflammation by reducing an innate lymphoid cell (ILC) inflammatory response in a subject in need thereof, comprising administering CGRP, thereby modulating a shift of naïve/quiescent ILC cells to type 2 ILC (ILC2) cells, wherein CGRP comprises β-CGRP.